Bioreactors Market size was USD 11.6 billion in 2024 and is estimated to reach USD 51.1 billion by the end of 2037, expanding at a CAGR of 12.1% during the forecast period, i.e., 2025-2037. In 2025, the industry size of bioreactors is estimated at USD 13 billion.
Governments and several pharma companies are investing heavily in research and development activities to introduce next-gen therapeutic solutions such as vaccines, gene therapies, antibiotics, and more to combat infectious diseases including, COVID-19. For instance, the Medical Countermeasures Gov revealed that the Biomedical Advanced Research and Development Authority (BARDA) in collaboration with the National Institute of Allergy and Infectious Disease is concentrating on the development of next-gen medical solutions such as vaccines and therapeutics to protect Americans from public health security threats such as coronaviruses.
Furthermore, in June 2024, the U.S. Department of Health and Human Services announced that BARDA awarded USD 500 million in Project NextGen funding for vaccine clinical trials. The funding is set to execute several Phase 2b clinical trials to evaluate novel vaccines administered as a nasal spray or pill to protect against symptomatic COVID-19. Such moves create profitable opportunities for bioreactor manufacturers, as bioreactor systems are necessary for the chemical reaction process in the developmental and clinical phases.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
12.1% |
|
Base Year Market Size (2024) |
USD 11.6 billion |
|
Forecast Year Market Size (2037) |
USD 51.1 billion |
|
Regional Scope |
|
Product Type (Single-use (Plastic), Reusable))
Reusable segment is set to capture around 74.5% bioreactors market share by the end of 2037. The main factor that is driving the sales of reusable bioreactors is their cost-effectiveness in the long term. The reusable bioreactors cut down the need for frequent purchases of single-use bags, liners, and other components, which leads to lower operational expenses for large-scale production. Large-scale biomanufacturing companies widely prefer employing reusable bioreactors due to their cost-effectiveness. Furthermore, many market players are advancing cleaning and sterilization technologies to make reusable bioreactors safer and more reliable. The integration of advanced materials that can withstand harsh cleaning cycles and high-performance environments is also boosting the efficiency of reusable bioreactors, contributing to their sales growth.
Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy, Others)
By the end of 2037, vaccines segment is expected to account for more than 50.2% bioreactors market share. The National Institutes of Health estimates that the use of bioreactors is high in cell culture-based viral vaccine production. The advanced bioreactors offer cost-effectiveness and convenience in the production of a high volume of vaccines to meet global demand. Furthermore, as the prevalence of infectious and non-infectious diseases such as influenza, malaria, and tuberculosis is increasing the demand for advanced bioreactors for efficient and scalable production of vaccines is gaining a boom. The ongoing advancements in biotechnology are anticipated to augment the demand for automated bioreactors for more efficient control of the production process.
Our in-depth analysis of the bioreactors market includes the following segments:
|
Product Type |
|
|
Cell |
|
|
Molecule |
|
|
Usage |
|
|
Material |
|
|
Size |
|
|
End use |
|
North America Market Forecast
By the end of 2037, North America bioreactors market is expected to capture around 37.7% share. The strong presence of biopharma companies and research organizations, and increasing investments by governments for the production of advanced therapeutic solutions are fuelling the sales of bioreactors.
In the U.S., the government’s supportive initiatives such as the National Biotechnology and Biomanufacturing Initiative to accelerate the biotechnology market growth are directly augmenting the sales of bioreactors. The supportive regulatory frameworks and funding to encourage research and production of biopharmaceuticals are boosting the demand for bioreactors. For instance, in December 2022, the U.S. Department of Energy invested USD 120 million in biotechnology and biomanufacturing innovations. Such investments further drive the adoption of bioreactors to carry out complex chemical reactions.
In Canada, the strong presence of research organizations such as the National Research Council Canada, CellCAN, and the Canadian Research Association that focuses on the production of regenerative medicines and cell therapies is contributing to the sales of bioreactors. High-performance bioreactors are essential in managing the high capacities of vaccine and drug manufacturing. Thus, the presence of advanced research organizations is creating lucrative opportunities for bioreactor manufacturers to earn high profits.
Asia Pacific Market Statistics
The Asia Pacific bioreactors market is calculated to expand at the fastest pace from 2025 to 2037. The rising biopharma product manufacturing, the growing need to improve healthcare infrastructure, and the increasing prevalence of chronic disorders are boosting the sales of advanced bioreactors. India, China, Japan, and South Korea are some of the high-growth marketplaces for bioreactors market.
In India, the increasing investments in expanding biopharma manufacturing and innovations in medical research and development sectors are pushing the sales of bioreactors. India has played a vital role during the COVID-19 pandemic by developing and exporting high volumes of vaccines across the world. According to the India Brand Equity Foundation, the National Biopharma Mission is supporting 101 projects including more than 150 organizations and 30 MSMEs. Such initiatives are driving the high adoption of automated bioreactors to carry out complex chemical reactions.
China’s rapidly expanding aging population is driving high demand for gene therapies, biologics, and biosimilars. The biopharma companies are investing heavily to accelerate the production cycles, which is increasing the adoption of high-performance bioreactors. As per the analysis by the Center for Strategic and International Studies, China is pitching to become a biotechnology powerhouse and in the past few years, it has invested over USD 100 billion in life sciences research and development. Such huge investment moves by the country are pushing a high demand for bioreactors.
The bioreactors market is quite competitive and to uplift their positions in the crowded space, leading companies are employing various organic and inorganic strategies. Technological innovations and new product launches are aiding them to mark a presence and stand out. Industry giants are collaborating with tech firms to integrate digital technologies and introduce automated bioreactors. This aids them in attracting a wider consumer base and earning high profits.
Some of the key players bioreactors market include:
Author Credits: Dhruv Bhatia
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?